trastuzumab


Also found in: Medical, Wikipedia.
Related to trastuzumab: tamoxifen

tras·tu·zu·mab

 (trăs-to͞o′zə-măb′)
n.
A humanized monoclonal antibody used intravenously to treat certain types of breast cancer and gastric cancer.

[tras-, origin unknown + tu(mor) + -zu- (shortening and alteration of humanized) + m(onoclonal) a(nti)b(ody).]
Mentioned in ?
References in periodicals archive ?
Neratinib (also called Nerlynx and marketed by Pierre Fabre) is recommended, under the terms of a commercial arrangement, for people with this type of breast cancer who are less than 1 year from completing trastuzumab (Herceptin)-based treatment following surgery (called adjuvant treatment).
Health Canada approval was based on the Phase III ExteNET trial, a multicenter, randomised, double-blind, placebo-controlled trial of neratinib following adjuvant trastuzumab treatment.
Reportedly, Health Canada's approval was based on the phase III ExteNET trial, a multicentre, randomised, double-blind, placebo-controlled trial of neratinib following adjuvant trastuzumab treatment.
Food and Drug Administration (FDA) has approved KANJINTI[TM] (trastuzumab-anns) for all approved indications of the reference product, Herceptin[R] (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Christiane Hamacher, chief executive officer of Biocon Biologies, said: "The final safety and overall survival data from the HERITAGE study for our biosimilar trastuzumab, Ogivri, cumulative through 36 months of follow-up, reconfirms that efficacy and safety is very similar to the reference product, Herceptin.
Sellas Life Sciences announced results from a preplanned analysis of immunologic responses in the cohort of patients with triple negative breast cancer, or TNBC, from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial of nelipepimut-S, or NPS, +/- trastuzumab targeting HER2 low-expressing breast cancer patients.
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201).
Contract notice: it is a trastuzumab active ingredient
- Collaboration combines Daiichi Sankyo's scientific and technological excellence with AstraZeneca's global experience and resources in oncology to accelerate and expand the potential of [fam-] trastuzumab deruxtecan as monotherapy and combination therapy across a spectrum of HER2 expressing cancers
Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease.
'In the era before Trastuzumab, HER2-positive breast cancer was a subgroup that had the worst prognosis,' Dr.
Daiichi Sankyo has entered into a clinical trial collaboration agreement with Merck KGaA and Pfizer to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in combination with the checkpoint inhibitor avelumab and/or an investigational Merck KGaA DNA damage response (DDR) inhibitor, in patients with HER2 expressing or mutated solid tumors.